Results from the Phase III SUNMO trial show that the Lunsumio and Polivy combination achieved statistically significant ...

Roche has demonstrated the power of combining two of oncology’s hottest modalities—bispecifics and antibody-drug conjugates ...

MAIA Biotechnology Inc., a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer ...

Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those ...

The pharma group has presented phase 1/2 results with new candidate NXT007 at the International Society on Thrombosis and ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

A suit cannot be maintained under the Civil law, merely based on an apprehension of litigation, without any concrete or ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

The commercial and clinical use of Elevidys was discontinued after two fatal cases of acute liver failure.

Alainy Chiloh Roché is ready to tee up for a career in medicine or real estate development, but she will continue to improve ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

The decision to advance prasinezumab to Phase III was based on results from the Phase IIb PADOVA trial, which demonstrated ...